{"preliminary_commentary":{"by_channel":{"youtube":46,"podcast":30,"x_thread":25,"bluesky_thread":1,"x_video":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04849364\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"PERSEVERE","nct_id":"NCT04849364","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=persevere-nct04849364. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"PERSEVERE","arms":[{"description":"Arm 1a: Patients who are ctDNA-positive and harbor a genomic target. DNA repair pathway = talazoparib + capecitabine (CLOSED)\n\nArm 1b: Patients who are ctDNA-positive and harbor a genomic target. Immunotherapy pathway = pembrolizumab + capecitabine (CLOSED)\n\nArm 1c: Patients who are ctDNA-positive and harbor a genomic target. PI3K Pathway = inavolisib + capecitabine ---\\> +/- standard of care pembrolizumab\n\nArm 1d: Patients who are ctDNA-positive and harbor a genomic target. DNA Repair + Immunotherapy = talazoparib + capecitabine +/- standard of care pembrolizumab","label":"Arm 1","type":"EXPERIMENTAL"},{"description":"Arm 2 subjects have plasma ctDNA positive but do not have a genomically driven treatment option. Treatment of physician's choice will be given with consideration for capecitabine and pembrolizumab. Dose, schedule and duration of treatment to be determined by treating physician.","label":"Arm 2","type":"ACTIVE_COMPARATOR"},{"description":"Arm 3 subjects have plasma ctDNA negative. Treatment of patient and physician's choice will be given with consideration for capecitabine and pembrolizumab. Dose, schedule and duration of treatment to be determined by treating physician.","label":"Arm 3","type":"ACTIVE_COMPARATOR"}],"collaborators":["Genentech, Inc.","Pfizer","Foundation Medicine","Indiana University","Vera Bradley Foundation for Breast Cancer"],"completion_date":{"date":"2024-12-02","type":"ACTUAL"},"conditions":["Breast Cancer","Triple Negative Breast Cancer"],"enrollment":{"count":52,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Capecitabine","otherNames":["Xeloda"],"type":"DRUG"},{"name":"Talazoparib","otherNames":["Talzenna"],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":["Keytruda"],"type":"DRUG"},{"name":"Inavolisib","otherNames":["GDC-0077"],"type":"DRUG"}],"last_update":"2025-05-31","lead_sponsor":"Bryan Schneider, MD","official_title":"A Phase II Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer (PERSEVERE)","overall_status":"TERMINATED","phases":["PHASE2"],"primary_completion_date":{"date":"2024-10-24","type":"ACTUAL"},"primary_outcomes":[{"measure":"ARM 1c: Disease Free Survival (DFS) at 2 Years","timeFrame":"2 years"}],"references":[],"start_date":{"date":"2021-08-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer","url":"https://clinicaltrials.gov/study/NCT04849364"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/persevere-nct04849364"}